Testosterone replacement therapy not associated with prostate cancer risk
1. In a population of men with hypogonadism and PSA concentrations less than 3 ng/mL, patients randomized to receive testosterone...
Urology
Reports of high-impact urology studies by medical professionals
Treatment of lower urinary tract symptoms in men in primary care using a conservative intervention
1. This randomised control trial demonstrated that a standardised and manualised intervention in primary care showed a sustained reduction in...
Risk of short-term prostate-specific antigen recurrence and failure in patients with prostate cancer
1. For patients with unfavorable nonmetastatic prostate cancer aged above 70 years, PSA levels above 10 ng/mL, and Gleason scores...
Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma
1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events...
Prophylactic antibiotics prevent urinary tract infections in infants with vesicoureteral reflux
1. In this randomized controlled trial, prophylactic antibiotics resulted in significantly lower rates of first-occurrence urinary tract infections (UTIs) in...
Decreased unnecessary urine cultures associated with decreased asymptomatic bacteriuria-related antibiotic use
1. This quality improvement study’s results suggested that more selective urine testing was conducted in 3 years as the percentage...
Shorter antibiotic therapy courses likely noninferior in the treatment of complicated urinary tract infections and bacteremia
1. In bacteremic patients with complicated UTI, a 10-day course of typical antibiotics or a 7-day course of IV beta-lactams...
Prostate cancer overscreening persists despite guideline changes
1. This retrospective cohort study demonstrated that males over the age of 70 are overscreened for prostate cancer, despite current...
Hydrochlorothiazide does not impact risk of kidney-stone recurrence
1. In this randomized controlled trial, among patients with recurrent kidney stones, hydrochlorothiazide did not alter the risk of symptomatic...
Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there...